Product: hnRNP A2/B1 Antibody
Catalog: DF3122
Description: Rabbit polyclonal antibody to hnRNP A2/B1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 36 KD; 37kD(Calculated).
Uniprot: P22626
RRID: AB_2835499

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:1000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
hnRNP A2/B1 Antibody detects endogenous levels of total hnRNP A2/B1.
Cite Format: Affinity Biosciences Cat# DF3122, RRID:AB_2835499.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


Heterogeneous nuclear ribonucleoprotein A2; Heterogeneous nuclear ribonucleoprotein A2/B1; Heterogeneous nuclear ribonucleoprotein B1; Heterogeneous nuclear ribonucleoproteins A2/B1; hnRNP A2 / hnRNP B1; hnRNP A2; hnRNP A2/B1; hnRNP B1; hnRNP-A2; hnRNP-B1; hnRNPA2; Hnrnpa2b1; hnRNPB1; HNRPA2; HNRPA2B1; HNRPB1; Nuclear ribonucleoprotein particle A2 protein; RNP A2; RNP B1; RNP-A2; RNP-B1; RNPA2; RNPB1; ROA2_HUMAN; SNRPB1;





Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P22626 As Substrate

Site PTM Type Enzyme
M1 Acetylation
K3 Acetylation
K3 Ubiquitination
T4 Phosphorylation
T7 Phosphorylation
K13 Ubiquitination
K22 Acetylation
K22 Ubiquitination
S29 Phosphorylation
T32 Phosphorylation
S36 Phosphorylation
R38 Methylation
Y40 Phosphorylation
Y41 Phosphorylation
K46 Acetylation
K46 Methylation
K46 Sumoylation
K46 Ubiquitination
T48 Phosphorylation
S58 Phosphorylation
K59 Acetylation
K59 Ubiquitination
S70 Phosphorylation
S71 Phosphorylation
S85 Phosphorylation
K94 Acetylation
K94 Ubiquitination
S102 Phosphorylation
K104 Acetylation
K104 Sumoylation
K104 Ubiquitination
K112 Acetylation
K112 Ubiquitination
K113 Ubiquitination
K120 Acetylation
K120 Sumoylation
K120 Ubiquitination
R129 Methylation
Y131 Phosphorylation
Y135 Phosphorylation
K137 Ubiquitination
T140 Phosphorylation
T145 Phosphorylation
R147 Methylation
S149 Phosphorylation
K151 Ubiquitination
R153 Methylation
T159 Phosphorylation O14757 (CHEK1)
K168 Acetylation
K168 Sumoylation
K168 Ubiquitination
K173 Acetylation
K173 Sumoylation
K173 Ubiquitination
Y174 Phosphorylation
T176 Phosphorylation
K186 Sumoylation
S189 Phosphorylation
S198 Phosphorylation
R200 Methylation
S201 Phosphorylation
R203 Methylation
S212 Phosphorylation
R213 Methylation
S225 Phosphorylation
R228 Methylation
S231 Phosphorylation
S236 Phosphorylation
R238 Methylation
Y244 Phosphorylation
Y247 Phosphorylation
S259 Phosphorylation
Y262 Phosphorylation
R266 Methylation
Y287 Phosphorylation
Y290 Phosphorylation
Y295 Phosphorylation
S297 Phosphorylation
Y300 Phosphorylation
Y306 Phosphorylation
S311 Phosphorylation
Y313 Phosphorylation
K317 Sumoylation
S318 Phosphorylation
S324 Phosphorylation
R325 Methylation
Y331 Phosphorylation
Y336 Phosphorylation
S341 Phosphorylation
S344 Phosphorylation
Y347 Phosphorylation
R350 Methylation
S351 Phosphorylation
R352 Methylation
Y353 Phosphorylation

Research Backgrounds


Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs. Forms hnRNP particles with at least 20 other different hnRNP and heterogeneous nuclear RNA in the nucleus. Involved in transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons: acts by specifically recognizing and binding the A2RE (21 nucleotide hnRNP A2 response element) or the A2RE11 (derivative 11 nucleotide oligonucleotide) sequence motifs present on some mRNAs, and promotes their transport to the cytoplasm. Specifically binds single-stranded telomeric DNA sequences, protecting telomeric DNA repeat against endonuclease digestion (By similarity). Also binds other RNA molecules, such as primary miRNA (pri-miRNAs): acts as a nuclear 'reader' of the N6-methyladenosine (m6A) mark by specifically recognizing and binding a subset of nuclear m6A-containing pri-miRNAs. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing binding of DGCR8 to pri-miRNA transcripts. Involved in miRNA sorting into exosomes following sumoylation, possibly by binding (m6A)-containing pre-miRNAs. Acts as a regulator of efficiency of mRNA splicing, possibly by binding to m6A-containing pre-mRNAs. Plays also a role in the activation of the innate immune response. Mechanistically, senses the presence of viral DNA in the nucleus, homodimerizes and is demethylated by JMJD6. In turn, translocates to the cytoplasm where it activates the TBK1-IRF3 pathway, leading to interferon alpha/beta production.

(Microbial infection) Involved in the transport of HIV-1 genomic RNA out of the nucleus, to the microtubule organizing center (MTOC), and then from the MTOC to the cytoplasm: acts by specifically recognizing and binding the A2RE (21 nucleotide hnRNP A2 response element) sequence motifs present on HIV-1 genomic RNA, and promotes its transport.


Sumoylated in exosomes, promoting miRNAs-binding.

Asymmetric dimethylation at Arg-266 constitutes the major methylation site (By similarity). According to a report, methylation affects subcellular location and promotes nuclear localization. According to another report, methylation at Arg-266 does not influence nucleocytoplasmic shuttling (By similarity).

Subcellular Location:

Nucleus. Nucleus>Nucleoplasm. Cytoplasm. Cytoplasmic granule. Secreted>Extracellular exosome.
Note: Localized in cytoplasmic mRNP granules containing untranslated mRNAs (PubMed:17289661). Component of ribonucleosomes (PubMed:17289661). Not found in the nucleolus (PubMed:17289661). Found in exosomes following sumoylation (PubMed:24356509).

Nucleus. Cytoplasm.
Note: Predominantly nucleoplasmic, however is also found in the cytoplasm of cells in some tissues (PubMed:17289661).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Homodimer; dimerization is required for nucleocytoplasmic translocation. Identified in the spliceosome C complex. Identified in a IGF2BP1-dependent mRNP granule complex containing untranslated mRNAs. Interacts with IGF2BP1. Interacts with C9orf72. Interacts with DGCR8. Interacts with TARDBP. Interacts with CKAP5. Interacts with TBK1. Interacts with STING1. Interacts with SRC.


The low complexity (LC) region is intrinsically disordered. When incubated at high concentration, it is able to polymerize into labile, amyloid-like fibers and form cross-beta polymerization structures, probably driving the formation of hydrogels. In contrast to irreversible, pathogenic amyloids, the fibers polymerized from LC regions disassemble upon dilution. A number of evidence suggests that formation of cross-beta structures by LC regions mediate the formation of RNA granules, liquid-like droplets, and hydrogels.


1). Quan L et al. HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma. Journal of Translational Medicine 2022 Nov 18;20(1):537. (PubMed: 36401285) [IF=7.4]

Application: WB    Species: Human    Sample: RPMI 8226 cells

Fig. 2 Adenovirus vector plasmid-mediated knockdown of HNRNPA2B1 in transfected RPMI 8226 cells and corresponding effects on cell proliferation and apoptosis. A Expression efficiency of GFP/RFP fluorescence of adenovirus vector plasmid in transfected RPMI 8226 cells after 72 h. Multiplicity of infection (MOI) refers to the number of virus particles infecting each cell. B qRT-PCR showed HNRNPA2B1 expression was significantly down-regulated at 72 h after transfection of RPMI 8226 cells with the adenoviral vector plasmid. C Western blotting showed HNRNPA2B1 protein expression was significantly down-regulated at 72 h after RPMI 8226 cells with the adenoviral vector plasmid. D CCK8 assay showing reduced proliferation of RPMI 8226 cells with HNRNPA2B1 knockdown compared with control cells. E Flow cytometric detection of apoptosis based on Annexin-V and PI staining in RPMI 8226 cells with HNRNPA2B1 knockdown versus control cells. Diagrams Q-UL, UR, LR, and LL represent necrotic, late apoptotic, early apoptotic, and live cells, respectively. F Statistical results from the apoptosis assay in E

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.